Tyrosine kinase inhibitors: a clinical perspective (Q34457414)

2 August 2017

0 references

1 reference

title

Tyrosine kinase inhibitors: a clinical perspective (English)

1 reference

2 August 2017

Sanjay Goel

1

1 reference

2 August 2017

Sridhar Mani

series ordinal

2

1 reference

2 August 2017

Roman Perez-Soler

series ordinal

3

1 reference

2 August 2017

1 January 2002

1 reference

2 August 2017

Current Oncology Reports

1 reference

2 August 2017

4

1 reference

2 August 2017

1

1 reference

2 August 2017

9-19

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-002-0043-x

2 August 2017

0 references

cites work

Protein-tyrosine kinases

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-002-0043-X

Signalling by receptor tyrosine kinases

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-002-0043-X

Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-002-0043-X

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

21 January 2018

1 reference

12 December 2020

Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells

1 reference

12 December 2020

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

1 reference

12 December 2020

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

12 December 2020

Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies

1 reference

12 December 2020

Transcriptional regulation by extracellular signals: mechanisms and specificity

1 reference

12 December 2020

In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

12 December 2020

Protein tyrosine kinase structure and function

1 reference

12 December 2020

Antisense therapeutics in oncology: points to consider in their clinical evaluation

1 reference

12 December 2020

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470).

1 reference

12 December 2020

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

1 reference

12 December 2020

Signal transduction by receptors with tyrosine kinase activity

1 reference

12 December 2020

Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes.

1 reference

12 December 2020

The Hallmarks of Cancer

1 reference

12 December 2020

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.

1 reference

12 December 2020

Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation

1 reference

12 December 2020

Altered efficacy and selectivity of tyrosine kinase inhibitors of the activated states of protein tyrosine kinases

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor

1 reference

12 December 2020

Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study

1 reference

12 December 2020

Dimerization of cell surface receptors in signal transduction

1 reference

12 December 2020

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

1 reference

12 December 2020

Kinetic model of the epidermal growth factor (EGF) receptor tyrosine kinase and a possible mechanism of its activation by EGF

1 reference

12 December 2020

Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior.

1 reference

12 December 2020

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions

1 reference

12 December 2020

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

12 December 2020

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

12 December 2020

1 reference

12 December 2020

Vertebrate non-receptor protein-tyrosine kinase families

1 reference

12 December 2020

Signal transduction by lymphocyte antigen receptors

1 reference

12 December 2020

Therapeutic application of anti-growth factor receptor antibodies

1 reference

12 December 2020

Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

1 reference

12 December 2020

1 reference

12 December 2020

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases

1 reference

12 December 2020

Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.

1 reference

12 December 2020

Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor.

1 reference

12 December 2020

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors

1 reference

12 December 2020

Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy

1 reference

12 December 2020

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

1 reference

12 December 2020

Endothelial receptor tyrosine kinases involved in angiogenesis.

1 reference

12 December 2020

Platelet-derived growth factor indirectly stimulates angiogenesis in vitro.

1 reference

12 December 2020

From form to function: signaling by protein tyrosine phosphatases.

1 reference

12 December 2020

The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice

1 reference

12 December 2020

10.1007/S11912-002-0043-X

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference